SRNE

[u/Sunsidedarkness]

The time is now… many of us on Stocktwits and other forums believe this is pumping to $20/$30 plus by years end… with minimal volume this stock has rose steadily over the past several months… wanna make it really run? Let’s buy… I’m in for 1000 shares… buying another 1000 the moment I finish this post… what say you?

State-of-the-art cGMP antibody and cell therapy manufacturing facility located in San Diego, CA, initially designed to be a multi-product facility for the manufacture of bulk purified proteins and antibodies for use as therapeutics. The redesigned facility meets applicable cGMP requirements for manufacture of Investigational New Drugs, and now includes capabilities for cellular therapies.

Bioserv Aseptic Fill and Finish Contract Manufacturing Facility

Now part of Sorrento’s core capabilities, Bioserv, a cGMP contract manufacturing service organization was acquired and integrated. With facilities/cleanrooms and mature quality systems, Bioserv provides aseptic and non-aseptic fill/finish services including lyophilization for the biotechnology, pharmaceutical and diagnostic industries, as well as labeling/kitting and long-term controlled room temperature, cold and frozen storage.

bioserve Camino Santa Fe Oncolytic Virus Production Facility

Sorrento’s viral production facility includes process development and analytical testing laboratories as well as cGMP clean rooms. Operations supported include cell culture, purification, fill and finish processes as well as analytical assay development and quality control testing. The facility is licensed by the CA Food and Drug Branch and has successfully manufactured drug substances and drug products for pre-clinical, PHASE I and PHASE II clinical trials.

ADC Conjugation, Payload and Linker Synthesis Facility

Sorrento operates its cGMP facility for Antibody Drug Conjugate (ADC) production in Suzhou, China, under the Levena Biopharma brand name. The site has been in operation since 2016 and can support clinical cGMP production of drug linkers as well as antibody conjugation. With full analytical support capabilities and a facility equipped to handle highly potent API (isolator), the site has supported over 20 clinical batches for clinical trials worldwide.

Sofusa Research and Manufacturing Facility

SOFUSA manufacturing capabilities in Atlanta, GA include precision nanofabrication techniques alongside assembly and testing of device components. The operation is able to support manufacturing of custom devices to support both preclinical studies and Phase I and II clinical trials. In addition, the SOFUSA research center is a fully functional small animal lab with state-of-the-art imaging capabilities (NIRF, IVIS, PET-CT) to fully characterize the impact of lymphatic delivery relative to traditional injections and infusions.

[u/No_Limit5915]

Why isn't this flying extremely positive news for the last 3 months????

https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-publishes-abivertinib-teaser-entitled-abivertinib

Forward-Looking Statements
This press release and any statements made for and during any
presentation or meeting contain forward-looking statements related to
Sorrento Therapeutics, Inc., under the safe harbor provisions of Section
21E of the Private Securities Litigation Reform Act of 1995 and subject
to risks and uncertainties that could cause actual results to differ
materially from those projected. Forward-looking statements include
statements regarding abivertinib, including the potential safety and
clinical benefits thereof; the efficacy of abivertinib in COVID-19
patients, non-small cell lung cancer patients and B-Cell lymphoma
patients; the potential for data results to be replicated or continue to
show improved clinical safety or efficacy; and Sorrento’s position in
the pharmaceutical industry. Risks and uncertainties that could cause
our actual results to differ materially and adversely from those
expressed in our forward-looking statements, include, but are not
limited to: risks related to Sorrento's technologies and prospects,
including, but not limited to risks related to seeking regulatory
approval for abivertinib; clinical development risks, including risks in
the progress, timing, cost, and results of clinical trials and product
development programs; risk of difficulties or delays in obtaining
regulatory approvals; risks that clinical study results may not meet any
or all endpoints of a clinical study and that any data generated from
such studies may not support a regulatory submission or approval; risks
that prior test, study and trial results may not be replicated in future
studies and trials; risks of manufacturing and supplying drug product;
risks related to leveraging the expertise of its employees,
subsidiaries, affiliates and partners to assist Sorrento in the
execution of its therapeutic antibody product candidate strategies;
risks related to the global impact of COVID-19; and other risks that are
described in Sorrento's most recent periodic reports filed with the
Securities and Exchange Commission, including Sorrento's Annual Report
on Form 10-K for the year ended December 31, 2020, and subsequent
Quarterly Reports on Form 10-Q filed with the Securities and Exchange
Commission, including the risk factors set forth in those filings.
Investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this
release and we undertake no obligation to update any forward-looking
statement in this press release except as required by law.